These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19020261)

  • 1. Implications of NSF-active and NSF-inert in nephrogenic systemic fibrosis.
    Wiginton CD
    AJR Am J Roentgenol; 2008 Dec; 191(6):1864-6. PubMed ID: 19020261
    [No Abstract]   [Full Text] [Related]  

  • 2. NSF-active and NSF-inert species of gadolinium: mechanistic and clinical implications.
    Kuo PH
    AJR Am J Roentgenol; 2008 Dec; 191(6):1861-3. PubMed ID: 19020260
    [No Abstract]   [Full Text] [Related]  

  • 3. Nephrogenic systemic fibrosis: some considerations on the debate regarding its cause.
    Provenzale JM
    AJR Am J Roentgenol; 2008 Dec; 191(6):1867-9. PubMed ID: 19020262
    [No Abstract]   [Full Text] [Related]  

  • 4. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis.
    Abraham JL; Edward M
    AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307
    [No Abstract]   [Full Text] [Related]  

  • 5. Nephrogenic systemic fibrosis.
    Kaewlai R; Abujudeh H
    AJR Am J Roentgenol; 2012 Jul; 199(1):W17-23. PubMed ID: 22733927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrogenic systemic fibrosis.
    Weinreb JC; Kuo PH
    Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathomechanisms of nephrogenic systemic fibrosis: new insights.
    Gupta A; Shamseddin MK; Khaira A
    Clin Exp Dermatol; 2011 Oct; 36(7):763-8. PubMed ID: 21790732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC; Abu-Alfa AK
    J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nephrogenic systemic fibrosis: a severe complication of use to gadolinium in patients with kidney failure].
    Mundim JS; Lorena Sde C; Abensur H; Elias RM; Moysés RM; Castro MC; Romão Júnior JE
    Rev Assoc Med Bras (1992); 2009; 55(2):220-5. PubMed ID: 19488662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?
    Panesar M; Boateng F; Patel SS; Masood SF; Mahajan P; Patel N; Murray B
    Hemodial Int; 2010 Jul; 14(3):289-94. PubMed ID: 20662951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on nephrogenic systemic fibrosis.
    Thomsen HS; Marckmann P; Logager VB
    Magn Reson Imaging Clin N Am; 2008 Nov; 16(4):551-60, vii. PubMed ID: 18926421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital.
    Zou Z; Ma L; Li H
    J Magn Reson Imaging; 2009 Dec; 30(6):1309-12. PubMed ID: 19937931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
    Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
    Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis.
    Bertero M; Bainotti S; Comino A; Formica M; Giordano F; Musso L; Palazzini S; Seia Z
    Eur J Dermatol; 2009; 19(1):73-4. PubMed ID: 19171533
    [No Abstract]   [Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
    Kribben A; Witzke O; Hillen U; Barkhausen J; Daul AE; Erbel R
    J Am Coll Cardiol; 2009 May; 53(18):1621-8. PubMed ID: 19406336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: a primer for radiologists.
    Prasad SR; Jagirdar J
    J Comput Assist Tomogr; 2008; 32(1):1-3. PubMed ID: 18303280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadolinium-based contrast agents and NSF: evidence from animal experience.
    Sieber MA; Steger-Hartmann T; Lengsfeld P; Pietsch H
    J Magn Reson Imaging; 2009 Dec; 30(6):1268-76. PubMed ID: 19938039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrogenic systemic fibrosis and management of high-risk patients.
    Altun E; Semelka RC; Cakit C
    Acad Radiol; 2009 Jul; 16(7):897-905. PubMed ID: 19375360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focus on contrast-associated nephrogenic systemic fibrosis.
    Partain CL
    J Magn Reson Imaging; 2009 Dec; 30(6):1231-2. PubMed ID: 19938033
    [No Abstract]   [Full Text] [Related]  

  • 20. Removal of gadolinium by dialysis: review of different strategies and techniques.
    Silberzweig JI; Chung M
    J Magn Reson Imaging; 2009 Dec; 30(6):1347-9. PubMed ID: 19937933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.